Literature DB >> 18279011

Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer.

Laura Seiboth1, Douglas Van Nostrand, Leonard Wartofsky, Yasser Ousman, Jacqueline Jonklaas, Calvin Butler, Frank Atkins, Kenneth Burman.   

Abstract

BACKGROUND: Approximately 30% of thyroid cancer patients present with reappearing disease within 40 years of initial diagnosis. Hence, sensitive postsurgical monitoring techniques are imperative to successful long-term care. The objective of this study was to assess the added clinical utility of a combined positron emission tomography/magnetic resonance imaging (PET/MRI) of the neck in conjunction with standard imaging in the detection of recurrent thyroid carcinoma. We define standard imaging as a neck sonogram, 131I scan, computed tomography, and MRI.
METHODS: This study included 34 patients treated for thyroid cancer at Washington Hospital Center. All patients had previously undergone near-total or total thyroidectomy, standard follow-up imaging studies, and laboratory studies. Twenty-nine of thirty-four patients had received at least one 131I treatment prior to the study. Each patient received a PET and MRI scan, and these images were subsequently digitally fused.
RESULTS: Individually and blinded, four endocrinologists retrospectively reviewed all information in patient charts prior to PET and PET/MRI coregistration. A clinical assessment and treatment plan were devised with these data. Following the initial assessment, the endocrinologists were provided results from the PET and PET/MRI fusion studies and asked to make a revised assessment and treatment plan. For each patient, the physicians categorized PET/MRI fusion results as providing new information that altered the initial treatment plan, providing new information that confirmed the initial treatment plan, or providing no additional information. On average, PET/MRI coregistration provided additional information that altered the treatment plan in 46% of the cases, provided additional information that confirmed the treatment plan in 36% of cases, and did not provide any additional information in 18% of cases.
CONCLUSION: The combination of structural and functional data that PET/neck MRI fusion offers provided further information in an overwhelming majority of thyroid cancer patients in this study. Thus PET/MRI can be a useful tool in surgical planning, radioactive iodine therapy decisions, and determining the level of follow-up necessary for each patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279011     DOI: 10.1089/thy.2007.0135

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  11 in total

Review 1.  Multimodality image registration with software: state-of-the-art.

Authors:  Piotr J Slomka; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

Review 2.  PET-MRI synergy in molecular, functional and anatomical cancer imaging.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 3.  Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer.

Authors:  Sungheon Gene Kim; Kent Friedman; Sohil Patel; Mari Hagiwara
Journal:  AJR Am J Roentgenol       Date:  2016-05-10       Impact factor: 3.959

4.  Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.

Authors:  James Nagarajah; Walter Jentzen; Verena Hartung; Sandra Rosenbaum-Krumme; Christian Mikat; Till Alexander Heusner; Gerald Antoch; Andreas Bockisch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-08       Impact factor: 9.236

5.  Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer.

Authors:  Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06       Impact factor: 9.236

6.  Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT?

Authors:  I Binse; T D Poeppel; M Ruhlmann; B Gomez; L Umutlu; A Bockisch; S J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-19       Impact factor: 9.236

Review 7.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review.

Authors:  Hyun Woo Kwon; Ann-Katharina Becker; Jin Mo Goo; Gi Jeong Cheon
Journal:  Nucl Med Mol Imaging       Date:  2016-04-07

8.  PET/MRI: a different spin from under the rim.

Authors:  Rodney J Hicks; Eddie W F Lau
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

9.  Speeding up PET/MR for cancer staging of children and young adults.

Authors:  Maryam Aghighi; Laura Jean Pisani; Ziyan Sun; Christopher Klenk; Himani Madnawat; Sandra Luna Fineman; Ranjana Advani; Rie Von Eyben; Daniel Owen; Andrew Quon; Michael Moseley; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2016-04-05       Impact factor: 5.315

10.  Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer.

Authors:  Denys J Loeffelbein; Michael Souvatzoglou; Veronika Wankerl; Julia Dinges; Lucas M Ritschl; Thomas Mücke; Anja Pickhard; Matthias Eiber; Markus Schwaiger; Ambros J Beer
Journal:  BMC Cancer       Date:  2014-11-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.